Asset profile

JS207

Multispecific antibody

Ungradedevidence

Evidence outlook

Completed readouts not yet graded

This drug has completed mid- or late-stage studies whose evidence has not yet been graded on this platform. Where a sponsor has not posted registry results, topline data typically arrives via company announcements — see News.

How the evidence outlook works ↗

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (1)
September 2026 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-09-04 · NCT06868836 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (4)
April 2027 (1)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-04-30 · NCT06944470 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (3)
Phase 1/2Solid TumorRecruiting
Est. primary completion 2027-12-31 · NCT07466160 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer …Recruiting
Est. primary completion 2027-12-31 · NCT05582499 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT06969027 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (1)
March 2028 (1)
Phase 2Triple-negative Breast CancerRecruiting
Est. primary completion 2028-03-22 · NCT07045311 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.